Singapore markets open in 6 hours 21 minutes

Valneva SE (0OB3.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
3.2340+0.0829 (+2.63%)
At close: 05:45PM BST
Full screen
Previous close3.1511
Open3.1680
Bid0.0000 x 0
Ask0.0000 x 0
Day's range3.1440 - 3.2500
52-week range2.8190 - 7.8420
Volume34,960
Avg. volume61,823
Market cap290.233M
Beta (5Y monthly)0.90
PE ratio (TTM)N/A
EPS (TTM)-0.7060
Earnings date13 Aug 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update

    Saint-Herblain (France), June 5, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company (“the Company”), today announced the availability of documentation for its Combined General Meeting (“the Meeting”) to be held on June 26, 2024 at 2:00 p.m. CEST at the Sofitel Lyon Bellecour Hotel, 20 quai du Docteur Gailleton, 69002 Lyon (France). The Preliminary Notice of Meeting – including the agenda, the draft resolutions proposed by the Board of Directors, and instructions f

  • GlobeNewswire

    VALNEVA - Declaration of shares and voting rights: May 31, 2024

    VALNEVA Declaration of shares and voting rights May 31, 2024__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)Regulated market of Euronext Paris - Compartment B Declaration date: June 4, 2024 Number of shares composing the share capital of ValnevaTotal number of voting rights including suspended voting rights*Description of the change Date on which this change was re

  • GlobeNewswire

    Valneva to Present and Hold Investor Meetings at Upcoming Conferences in June

    Saint-Herblain (France), June 4, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that management will participate at several upcoming investor conferences in the United States and Europe during June 2024. Valneva will present and meet with global institutional investors to discuss VLA15, the world’s leading Lyme Disease vaccine candidate, in Phase 3 development and partnered with Pfizer; the Company’s growing commercial business, including ongo